Search Results - "Rodas, I. Márquez"

The RANK–RANKL axis: an opportunity for drug repurposing in cancer? by Peters, S., Clézardin, P., Márquez-Rodas, I., Niepel, D., Gedye, C.

“…Drug repurposing offers advantages over traditional drug development in terms of cost, speed and improved patient outcomes. The receptor activator of nuclear…”
Get full text

Running away from side effects: physical exercise as a complementary intervention for breast cancer patients by Casla, S., Hojman, P., Márquez-Rodas, I., López-Tarruella, S., Jerez, Y., Barakat, R., Martín, M.

“…The number of breast cancer survivors increases every year, thanks to the development of new treatments and screening techniques. However, patients present…”
Get full text

Efficacy and safety of immune checkpoint inhibitor immunotherapy in elderly cancer patients by Fox, B., de Toro Carmena, M., Álvarez Álvarez, R., Calles Blanco, A., López López, C., Pérez Ramírez, S., Arranz, J. Á., Martín, M., Márquez-Rodas, I.

“…Purpose There is limited evidence on the efficacy and safety of anti-programmed cell death protein 1 (PD-1)-/anti-programmed death-ligand 1 (PD-L1)-based…”
Get full text

SEOM clinical guideline for the management of malignant melanoma (2017) by Berrocal, A., Arance, A., Castellon, V. E., de la Cruz, L., Espinosa, E., Cao, M. G., Larriba, J. L. G., Márquez-Rodas, I., Soria, A., Algarra, S. M.

“…All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with…”
Get full text

A retrospective chart review study describing metastatic melanoma patients profile and treatment patterns in Spain by Márquez-Rodas, I., Arance, A., Berrocal, A., Larios, C. L., Curto-García, J., Campos-Tapias, I. X., Blanca, A. B., Martin-Algarra, S.

“…Purpose To describe patient characteristics by disease stage, resectability status and current treatment management after first diagnosis of IIIB to IV1c…”
Get full text

ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee by Keilholz, U., Ascierto, P.A., Dummer, R., Robert, C., Lorigan, P., van Akkooi, A., Arance, A., Blank, C.U., Chiarion Sileni, V., Donia, M., Faries, M.B., Gaudy-Marqueste, C., Gogas, H., Grob, J.J., Guckenberger, M., Haanen, J., Hayes, A.J., Hoeller, C., Lebbé, C., Lugowska, I., Mandalà, M., Márquez-Rodas, I., Nathan, P., Neyns, B., Olofsson Bagge, R., Puig, S., Rutkowski, P., Schilling, B., Sondak, V.K., Tawbi, H., Testori, A., Michielin, O.

“…The European Society for Medical Oncology (ESMO) held a consensus conference on melanoma on 5–7 September 2019 in Amsterdam, The Netherlands. The conference…”
Get full text

ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee by Michielin, O., van Akkooi, A., Lorigan, P., Ascierto, P.A., Dummer, R., Robert, C., Arance, A., Blank, C.U., Chiarion Sileni, V., Donia, M., Faries, M.B., Gaudy-Marqueste, C., Gogas, H., Grob, J.J., Guckenberger, M., Haanen, J., Hayes, A.J., Hoeller, C., Lebbé, C., Lugowska, I., Mandalà, M., Márquez-Rodas, I., Nathan, P., Neyns, B., Olofsson Bagge, R., Puig, S., Rutkowski, P., Schilling, B., Sondak, V.K., Tawbi, H., Testori, A., Keilholz, U.

“…The European Society for Medical Oncology (ESMO) held a consensus conference on melanoma on 5–7 September 2019 in Amsterdam, The Netherlands. The conference…”
Get full text

3540 POSTER Perception of Hereditary Cancer Risk in a Medical Oncology Service: a Retrospective Study by Márquez-Rodas, I, Trabada, D. López, Cabello, S. Custodio, Blanco, A. Rupérez, Clemente, M. Orera, Gómez, M.I. Peligros, Solís, R. Mondejar, Calvo, F, Martin, M

Get full text

Pathophysiology and therapeutic possibilities of calcitonin gene-related peptide in hypertension by Márquez-Rodas, I, Longo, F, Rothlin, R P, Balfagón, G

“…Calcitonin gene related peptide (CGRP), a 37 amino acid neuropeptide, is the most potent vasodilator known. Participation of CGRP in hypertension and related…”
Get full text

Venous thromboembolism incidence in cancer patients with germline BRCA mutations by Muñoz, A. J., de Toro, M., Ortega, L., López, C., Gutiérrez, A., Juliao, D. S., Arregui, M., Lobato, N., Echavarría, I., Márquez-Rodas, I., Martín, M.

“…Background Germline BRCA (gBRCA) mutations predispose to an increased risk of breast and ovarian cancer among other neoplasms. Recently, several genomic…”
Get full text

Utility of PET/CT in patients with stage I–III melanoma by Avilés Izquierdo, J. A., Molina López, I., Sobrini Morillo, P., Márquez Rodas, I., Mercader Cidoncha, E.

“…Purpose To study the utility of positron emission tomography with computerized tomography (PET/CT) in patients with a stage I–III melanoma. Patients and…”
Get full text

Five Years of Multidisciplinary Care in Hereditary Cancer: Our Experience in a Spanish University Hospital by Márquez-Rodas, I, Lobo, M, Flores-Sanchez, C, Sanz, M, Luque, S, Lizarraga, S, González-Asanza, C, Pajares, J A, Peligros, M I, Bueno, O, Mata, C, Lopez, C, López-Tarruella, S, Jerez, Y, Muñoz-Martin, A, Blanco, M, Die-Trill, M, Justel, J P, Solera, J, Martin, M

“…To analyse the evolution of a multidisciplinary heredofamilial cancer unit (HFCU) in a university hospital. This was a retrospective analysis of the activity…”
Get more information

Review: circulating tumor cells in the practice of breast cancer oncology by Ramos-Medina, R., Moreno, F., Lopez-Tarruella, S., del Monte-Millán, M., Márquez-Rodas, I., Durán, E., Jerez, Y., Garcia-Saenz, J. A., Ocaña, I., Andrés, S., Massarrah, T., González-Rivera, M., Martin, M.

“…The primary cause of tumor-related death in breast cancer is still represented by distant metastasization. The dissemination of tumor cells from the primary…”
Get full text

Epidemiological changes in cutaneous melanoma: retrospective study of 969 cases (1996-2010) by Avilés-Izquierdo, J A, Lázaro-Ochaita, P, Suárez-Fernández, R, Márquez-Rodas, I, Parra-Blanco, V, Escat-Cortés, J L

“…BACKGROUNDThe incidence of malignant melanoma has increased over recent decades all over the world; however, we are not aware if this also occurs in Madrid…”
Get full text

SEOM clinical guideline for the management of cutaneous melanoma (2020) by Majem, M., Manzano, J. L., Marquez-Rodas, I., Mujika, K., Muñoz-Couselo, E., Pérez-Ruiz, E., de la Cruz-Merino, L., Espinosa, E., Gonzalez-Cao, M., Berrocal, A.

“…Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish…”
Get full text

Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511) by Lebbé, C., Meyer, N., Mortier, L., Marquez-Rodas, I., Robert, C., Rutkowski, P., Menzies, A.M., Eigentler, T., Ascierto, P.A., Smylie, M., Ajaz, M., Svane, I.-M., Gonzalez, R., Rollin, L., Saci, A., Grigoryeva, E., Pigozzo, J.

Get full text

Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors by Marquez Rodas, I., Longo, F., Rodriguez-Ruiz, M., Calles, A., Pérez-Gracia, J.L., Gomez-Rueda, A., Lopez-Tarruella, S., Ponz-Sarvisé, M., Alvarez, R.M., Soria, A., de-Miguel, E., Gayarre, J., Aznar, M.A., Calvo, A., Lopez-Casas, P.P., Tersago, D., Quintero, M., Martin-Algarra, S., Martín, M., Melero, I.

Get full text

Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067) by Hodi, F.S., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Rutkowski, P., Cowey, C.L., Lao, C., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P.F., Smylie, M., Hill, A.G., Hogg, D., Marquez-Rodas, I., Jiang, J., Rizzo, J., Larkin, J., Wolchok, J.

Get full text

MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours by Tanic, M, Andrés, E, M Rodriguez-Pinilla, S, Marquez-Rodas, I, Cebollero-Presmanes, M, Fernandez, V, Osorio, A, Benítez, J, Martinez-Delgado, B

“…Background: Hereditary breast cancer comprises 5–10% of all breast cancers. Mutations in two high-risk susceptibility genes, BRCA1 and BRCA2, along with rare…”
Get full text

Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study by Chatziioannou, E., Higuita, L.M. Serna, Kreft, S., Kandolf, L., Dujovic, B., Reinhardt, L., Tamara, E., Marquez-Rodas, I., Fortuna, A.R.F.P., Nübling, A., Niessner, H., Forschner, A., Garbe, C., Popovic, A., Mirjana, B., Meier, F., Eigentler, T., Leiter, U., Flatz, L., Sinnberg, T., Amaral, T.

“…The introduction of anti-programmed cell death protein 1 (PD-1) immunotherapy has revolutionized the treatment landscape for melanoma, enhancing both response…”
Get full text